MitoSense is Supporting Targeting Mitochondria 2024



MitoSense will be sponosring the the 15th WMS Annual Meeting, Targeting Mitochondria 2024, on October 29-31 at DoubleTree by Hilton Berlin Ku'damm, Berlin, Germany.

About MitoSense

MitoSense, Inc. is a research and development company in the field of securing development of treatments for neurodegenerative diseases. With exclusively licensed technology to replenish the mitochondria in humans using Mitochondria Organelle Transplantation (MOT™️), the company, through its U.S. based research partner is initially focusing its efforts on treating ALS. MOT™️ may impact research for  patients with Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative diseases, none of which have a cure. 

What do they do?

MitoSense uses a proprietary (patent pending) technique to replenish mitochondria to treat ALS. The technique has the potential to treat a wide range of indications including Alzheimer’s, Parkinson’s, Huntington’s, Multiple Sclerosis and other neurodegenerative diseases. With experienced leadership in business, government, research, and medical, we have brought together a multidisciplinary team to help in the fight. 

Talk at Targeting Mitochondria 2024:

KindyDr. Mark Kindy, CEO at MitoSense will be presenting a major talk during the  meeting in Berlin: "Mitochondrial Transplantation Mediates Improved Cellular Energy Metabolism, Restoration of Mitochondrial Function and Prevention of Cell Death"

In his talk Dr. Kindy will cover:

  1. Isolation and characterization of mitochondria
  2. Application of mitochondrial transplantation
  3. Reversal of cellular dysfunction
  4. Restoration of energy metabolism

MitoSense Website: 

Mitochondria in the Press & Media

  • 1
  • 2
Prev Next


News archive